This module is not currently running in 2024 to 2025.
A synopsis of the curriculum;
Infectious diseases:
- Microbial infection and control
- Infections by body systems
- Chemotherapy and Infection Control
- Vaccines
Clinical Pharmacokinetics:
- Variability in drug handling
- Dosage regimen design and therapeutic drug monitoring (TDM)
Cancer Biology:
- Introduction to cell biology of cancer
- Genetic damage, repair and mutation
- Tumour growth
- Growth factors and oncogene
- Growth inhibition and tumour suppressor genes
- Diet, hormones and cancer
- Treatment of cancer
Lectures (45 hours), Practicals/Workshops (165 hours), MSCL/CAL (90 hours)
60% examination, 40% continuous assessment and satisfactory attendance at laboratory/ workshop/ seminar sessions is required
Greenwood, D. (2005) Antimicrobial chemotherapy, Oxford University Press
Greenwood, D. (2007) Antimicrobial chemotherapy, Oxford University Press
Mims, C.A. et al (2004) Medical Microbiology 3rd Edition, Mosby
Goering, R. et al (2007) Medical Microbiology 4th Edition, Mosby
Heyman, D.L. (2008) Control of Communicable Diseases Manual, American Public Health Association
Pecorino, L. (2005) Molecular Biology of Cancer, Oxford University Press
Pecorino, L. (2008) Molecular Biology of Cancer 2nd Revised Edition, Oxford University Press
Rowland, M. & Tozer, T. (1995) Clinical Pharmacokinetics: Concepts and Applications 3rd Edition, Lippincott, Williams & Wilkins
Tozer T. & Rowland, M. (2006) Introduction to Pharmacokinetics and Pharmacodynamics: The Quantitative Basis of Drug Therapy, Lippincott, Williams & Wilkins
Winter, M.E. (1994) Basic Clinical Pharmacokinetics 3rd Edition, Lippincott, Williams & Wilkins
Winter, M.E. (2003) Basic Clinical Pharmacokinetics 4th Revised Edition, Lippincott, Williams & Wilkins
A systematic understanding of the pathogenic processes by which a wide range of organisms cause disease in humans and how these are spread (PO16, PO19, PO38, PO39, PO43)
An ability to identify the general symptoms exhibited by patients suffering from conditions caused by an infection and make judgements about treatment options taking into account modes of action of chemotherapeutic agents, patterns of resistance and the clinical needs of the patient (PO4, PO5, PO17, PO20, PO21, PO38, PO39, PO53)
An ability to critically review pharmacokinetic data and interpret in the light of factors which may affect patient variability (PO18, PO20, PO38, PO40, PO53)
A systematic understanding of key aspects of the cellular basis of oncology and describe the principles of neoplastic therapy (PO1, PO5, PO16, PO17, PO18, PO20, PO21, PO38, PO50, PO52)
A systematic understanding of the need for and methods used to monitor drugs which require individualised dosing and an ability to interpret associated clinical data (PO38, PO41, PO44, PO53)
An ability to investigate and critically appraise recent therapeutic advances in the prevention and treatment of viral, bacterial and other infective conditions (PO7, PO8, PO22, PO41)
University of Kent makes every effort to ensure that module information is accurate for the relevant academic session and to provide educational services as described. However, courses, services and other matters may be subject to change. Please read our full disclaimer.
